Showing 1411-1420 of 1535 results for "".
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2
- Survey Reveals Attitudes About Lip Healthhttps://practicaldermatology.com/news/survey-reveals-attitudes-about-lip-health/2458937/The majority of Americans suffer from dry and chapped lips, and 1 in 4 say that when their lips are chapped and flaky they don’t look attractive. Furthermore, close to 1 in 5 say their self-confidence goes down when their lips are chapped and flaky and, some even
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- Aclaris Therapeutics' A-101 Achieves Positive Results in Clinical Trial for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-a-101-achieves-positive-results-in-clinical-trial-for-seborrheic-keratosis/2458989/Aclaris Therapeutics, Inc.’s lead drug candidate A-10 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face in its third Phase II clinical trial. The double-blind, vehicle-controlled Phase 2 clinical trial was designed t
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDAhttps://practicaldermatology.com/news/leo-pharma-submits-nda-for-aerosol-foam-for-psoriasis-to-fda/2459033/LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed w
- Michael R. Stewart Named Next President and CEO of MELA Scienceshttps://practicaldermatology.com/news/20141119-micheal_r_stewart_named_next_president_and_ceo_of_mela_sciences/2459057/MELA Sciences, Inc. developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, announced that its Board of Directors has named Michael R. Stewart, 57, as the company's n